Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1-Reference-Cited by-同舟云学术

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Published:2019-03-11 Issue:8 Volume:33 Page:1910-1922
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pfeifer H.,Cazzaniga G.,van der Velden V. H. J.,Cayuela J. M.,Schäfer B.,Spinelli O.^ORCID,Akiki S.,Avigad S.,Bendit I.,Borg K.,Cavé H.,Elia L.,Reshmi S. C.,Gerrard G.^ORCID,Hayette S.,Hermanson M.,Juh A.,Jurcek T.,Chillón M. C.,Homburg C.,Martinelli G.,Kairisto V.,Lange T.,Lion T.,Mueller M. C.,Pane F.,Rai L.,Damm-Welk C.,Sacha T.,Schnittger S.,Touloumenidou T.,Valerhaugen H.,Vandenberghe P.,Zuna J.,Serve H.,Herrmann E.,Markovic S.,Dongen J. J. M. van,Ottmann O. G.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0413-0.pdf

Reference56 articles.

1. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.

2. Brisco J, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 1996;87:5251–6.

3. Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.

4. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591–8.

5. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study;Journal of Clinical Oncology;2024-09-10

2. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

3. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions;Leukemia;2024-06-20

4. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications;Current Hematologic Malignancy Reports;2024-06-18

5. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia;Blood;2024-06-06